Table 1 Distribution of tumor entities for all benign, malignant and non-neoplastic soft tissue masses ≤5 cm, ≤3 cm and ≤2 cm included in this study
From: Soft tissue masses: distribution of entities and rate of malignancy in small lesions
Benign | Malignant | Non-neoplastic | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Entity | ≤5 cm | ≤3 cm | ≤2 cm | Entity | ≤5 cm | ≤3 cm | ≤2 cm | Entity | ≤5 cm | < 3 cm | ≤2 cm |
Overall | 562 (64.6%) | 330 (69.77%) | 159 (66.25%) | 195 (22.41%) | 78 (16.49%) | 36 (15.0%) | 113 (12.99%) | 65 (13.74%) | 45 (18.75%) | ||
Deep benign fibrous histiocytoma | 1 (0.11%) | – | – | Alveolar soft part sarcoma | 4 (0.46%) | – | – | Bursitis | 6 (0.69%) | 4 (0.85%) | 3 (1.26%) |
Fibroma | 33 (3.79%) | 26 (5.5%) | 16 (6.67%) | Angiosarcoma of soft tissue | 6 (0.69%) | 2 (0.43%) | – | Ganglion | 65 (7.47%) | 42 (8.88%) | 27 (11.3%) |
Fibromatosis | 40 (4.6%) | 25 (5.5%) | 14 (5.83%) | Chondrosarcoma | 2 (0.23%) | 1 (0.21%) | – | Haematoma | 5 (0.57%) | 1 (0.21%) | 1 (0.42%) |
Glomus tumors | 1 (0.11%) | – | – | Clear cell sarcoma of soft tissue | 3 (0.34%) | 1 (0.21%) | 1 (0.42%) | Lipoma arborescens | 2 (0.23%) | – | – |
Haemangioma | 74 (8.51%) | 48 (10.15%) | 20 (8.33%) | Dermatofibrosarcoma protuberans | 7 (0.8%) | 5 (1.06%) | 3 (1.25%) | Pseudotumor | 12 (1.38%) | 5 (1.06%) | 3 (1.26%) |
Hamartoma | 1 (0.11%) | 1 (0.21%) | 1 (0.42%) | Epithelioid sarcoma | 4 (0.46%) | 3 (0.63%) | 1 (0.42%) | Others | 23 (2.64%) | 13 (2.75%) | 11 (4.6%) |
Hibernoma | 1 (0.11%) | – | . | Ewing-Sarcoma | 2 (0.23%) | 1 (0.21%) | 1 (0.42%) | ||||
Lipoma | 97 (11.15%) | 34 (7.19%) | 12 (5.0%) | Extraskeletal osteosarcoma | 1 (0.11%) | – | – | ||||
Lymphangioma | 1 (0.11%) | – | – | Extrapleural solitary fibrous tumour | 6 (0.69%) | 1 (0.21%) | 1 (0.42%) | ||||
Myopericytoma | 3 (0.34%) | 2 (0.42%) | 2 (0.83%) | Fibrosarcoma | 5 (0.57%) | 5 (1.06%) | 2 (0.83%) | ||||
Myositis ossificans | 2 (0.23%) | 2 (0.42%) | – | Haemangioendothelioma | 1 (0.11%) | 1 (0.21%) | 1 (0.42%) | ||||
Myxoma | 21 (2.41%) | 7 (1.48%) | 3 (1.25%) | Leyomyosarcoma | 18 (2.07%) | 10 (2.11%) | 6 (2.5%) | ||||
Nodular fasciitis | 25 (2.87%) | 19 (4.02%) | 13 (5.42%) | Liposarcoma a | 27 (3.1%) | 6 (1.27%) | 3 (1.25%) | ||||
Perineurioma | 1 (0.11%) | – | – | Lymphoma | 7 (0.8%) | 1 (0.21%) | – | ||||
Schwannoma | 92 (10.57%) | 63 (13.32%) | 27 (11.25%) | Metastasis | 6 (0.69%) | 2 (0.42%) | 1 (0.42%) | ||||
Tenosynovial giant cell tumor | 169 (19.43%) | 102 (21.56%) | 51 (21.25%) | Malignant peripheral nerve sheath tumor | 1 (0.11%) | – | – | ||||
Myofibroblastic tumor | 6 (0.69%) | 5 (1.06%) | 1 (0.42%) | ||||||||
Myxofibrosarcoma | 24 (2.76%) | 7 (1.48%) | 5 (2.08%) | ||||||||
Rhabdomyosarcoma | 4 (0.46%) | 1 (0.21%) | – | ||||||||
Synovial sarcoma | 20 (2.3%) | 9 (1.9%) | 3 (1.25%) | ||||||||
Undifferentiated pleomorphic sarcoma | 34 (3.91%) | 12 (2.54%) | 5 (2.08%) | ||||||||
Sarcoma, not otherwise specified | 7 (0.8%) | 5 (1.06%) | 2 (0.83%) | ||||||||